ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...

CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study ...

NYSE:PFE) Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

( NASDAQ: IBRX ), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the ...

New safeguards against artificial intelligence deepfakes. The California Legislature passed hundreds of bills in 2024, many of which go into effect on Jan. 1 and touch nearly every aspect of life ...

California lawmakers passed roughly 1,200 bills last year, including some that resulted in unforeseeable wins by Republicans, promising protections for consumers and small strides for those in the ...

SACRAMENTO, Calif — New year, new laws. Hundreds of laws were passed by California Governor Gavin Newsom. By 2025, a number of those laws are set to go into effect — along with some from years ...

Copyright 2025 The Associated Press. All Rights Reserved. A fire burns a house in the Mountain fire, Wednesday, Nov. 6, 2024, in Camarillo, Calif. (AP Photo/Marcio ...